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Abstract
Background: A recent study investigated the MYLIP region in the Mexican population in order to fine-map the
actual susceptibility variants of this locus. The p.N342S polymorphism was identified as the underlying functional
variant accounting for one of the previous signals of genome-wide association studies and the N342 allele was
associated with higher cholesterol concentrations in Mexican dyslipidemic individuals. To date, there is no further
evaluation on this genotype-phenotype association in the literature. In this scenario, and because of a possible
pharmacotherapeutic target of dyslipidemia, the main aim of this study was to assess the influence of the MYLIP
p.N342S polymorphism on lipid profile in Brazilian individuals.
Methods: 1295 subjects of the general population and 1425 consecutive patients submitted to coronary
angiography were selected. General characteristics, biochemical tests, blood pressures, pulse wave velocity, and
coronary artery disease scores were analyzed. Genotypes for the MYLIP rs9370867 (p.N342S, c.G1025A)
polymorphism were detected by high resolution melting analysis.
Results: No association of the MYLIP rs9370867 genotypes with lipid profile, hemodynamic data, and coronary
angiographic data was found. Analysis stratified by hyperlipidemia, gender, and ethnicity was also performed and
the sub-groups presented similar results. In both general population and patient samples, the MYLIP rs9370867
polymorphism was differently distributed according to ethnicity. In the general population, subjects carrying GG
genotypes had higher systolic blood pressure (BP), diastolic BP, and mean BP values (129.0 ± 23.3; 84.9 ± 14.6;
99.5 ± 16.8 mmHg) compared with subjects carrying AA genotypes (123.7 ± 19.5; 81.6 ± 11.8; 95.6 ± 13.6 mmHg)
(p = 0.01; p = 0.02; p = 0.01, respectively), even after adjustment for covariates. However, in analysis stratified by
ethnicity, this finding was not found and there is no evidence that the polymorphism influences BP.
Conclusion: Our findings indicate that association studies involving this MYLIP variant can present distinct results
according to the studied population. In this moment, further studies are needed to reaffirm if the MYLIP p.N342S
polymorphism is functional or not, and to identify other functional markers within this gene.
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Background
Lipid profile disorders have been significantly associated
with risk of cardiovascular disease (CVD), which is also
influenced by genetic factors, hypertension, type 2 dia-
betes mellitus, obesity, and smoking. CVD are the main
cause of morbidity and mortality in developed countries
and the financial cost is enormous. Thus, guidelines
from the National Cholesterol Education Program
(NCEP) rely on low-density lipoprotein cholesterol
(LDL-C) for the prevention of CVD [1-6].
A conventional lipid panel reports several parameters,
including total cholesterol (TC), LDL-C, high-density
lipoprotein cholesterol (HDL-C), and triglycerides. Of
these, the NCEP and the American Heart Association
recommend using LDL-C as a primary target of therapy
in conjunction with assessing cardiovascular risk factors.
The Third Report of the Expert Panel on Detection,
Evaluation, and Treatment of High Blood Cholesterol in
Adults (Adult Treatment Panel III, or ATP III - NCEP)
updated clinical guidelines for cholesterol testing such as
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high TC (≥ 240 mg/dL), high LDL-C (≥ 160 mg/dL), and
low HDL-C (< 40 mg/dL) [3,7,8].
Population genetic and epidemiological studies could
help to assess the etiologic role of lipid profile in CVD
and, novel genetic determinants of blood lipids can also
help to provide new insights into the biological pathways
and identify novel therapeutic targets. In this way,
current genome-wide association studies (GWAS) have
identified genetic loci contributing to inter-individual
variation in serum concentration of lipids [9-12]. Some
GWAS, using cohorts of mixed European descent, iden-
tified non-coding polymorphisms in the region of the
MYLIP gene that were associated with LDL-C concen-
trations [12-14]. The MYLIP functional variant and the
mechanistic basis of these associations were recently
postulated by Weissglas-Volkov et al. [15].
MYLIP gene encodes a regulator of the LDL receptor
pathway for cellular cholesterol uptake called MYLIP
(myosin regulatory light chain interacting protein; also
known as IDOL). Weissglas-Volkov et al. investigated
the MYLIP region in the Mexican population in order to
fine-map the actual susceptibility variants. They identi-
fied the rs9370867 non-synonymous polymorphism (p.
N342S) as the underlying functional variant accounting
for one of the previous GWAS significant signals and
associated N342 allele with higher TC concentrations in
Mexican dyslipidemic individuals [15].
To date, there is no further evaluation on this
genotype-phenotype association (MYLIP p.N342S – lipid
profile). In this scenario, the main aim of this study was
to assess the influence of the MYLIP polymorphism on
lipid profile in Brazilian individuals.
Methods
General population
One thousand two hundred ninety-five subjects of the
general urban population were selected from Vitoria,
Brazil [16]. The study design was based on cross-
sectional research methodology and was developed by
means of surveying and analyzing socioeconomic and
health data in a probabilistic sample of residents from
the municipality of Vitoria, Espirito Santo, Brazil. The
sampling plan had the objective of ensuring that the re-
search would be socioeconomically, geographically, and
demographically representative of the residents of this
municipality. The study protocol was approved by the
involved Institutional Ethics Committees and written
informed consent was obtained from all participants
prior to enter the study.
Patients submitted to coronary angiography
One thousand four hundred twenty-five consecutive
patients submitted to coronary angiography for the first
time to study suggestive coronary artery disease etiology
were selected at the Laboratory of Hemodinamics, Heart
Institute (Incor), Sao Paulo, Brazil. All patients had a
clinical diagnosis of angina pectoris and stable angina.
No patient enrolled in this study was currently experien-
cing an acute coronary syndrome. Patients with previous
acute ischemic events, heart failure classes III–IV, hep-
atic dysfunction, familiar hypercholesterolemia, previous
heart or kidney transplantation, and in antiviral treat-
ment were excluded [17-19]. Patients answered a clinical
questionnaire that covered questions regarding personal
medical history, family antecedents of CVD, sedentar-
ism, smoking status, hypertension, obesity, dyslipidemia,
diabetes, and current treatment. All patients signed an
informed consent form and the study has been approved
by the local Ethics committee.
Demographic data and laboratory tests
Weight and height were measured according to a stand-
ard protocol, and body mass index (BMI) was calculated.
Individuals answered a clinical questionnaire that cov-
ered questions regarding smoking status and current
medical treatment. Individuals who had ever smoked
more than five cigarettes per day for the last year were
classified as smokers [1,20]. Ethnicity was classified with
a validated questionnaire for the Brazilian population
according to a set of phenotypic characteristics (such as
skin color, hair texture, shape of the nose and aspect of
the lip) and individuals were classified as White, Inter-
mediate (meaning Brown, Pardo in Portuguese), Black,
Amerindian or Oriental descent [16,21,22].
Triglycerides (TG), TC, HDL-C, LDL-C, and glucose
were evaluated by standard techniques in 12-h fasting
blood samples. Diabetes mellitus was diagnosed by the
presence of fasting glucose ≥ 126 mg/dL or the use of
antidiabetic drugs [23]. Hyperlipidemia was defined as
TC ≥ 240 mg/dL, LDL-C ≥ 160 mg/dL, and/or use of
hypolipidemic drugs [7].
Blood pressure phenotypes
Blood pressure was measured in the sitting position with
the use of a standard mercury sphygmomanometer on
the left arm after 5 min rest. The first and fifth phases of
Korotkoff sounds were used for systolic blood pressure
(SBP) and diastolic blood pressure (DBP), respectively.
The SBP and DBP were calculated from two readings
with a minimal interval of 10 min apart. Hypertension
was defined as mean SBP ≥140 mmHg and/or DBP
≥90 mm Hg and/or antihypertensive drug use [24]. The
mean blood pressure (MBP) was calculated as the mean
pulse pressure added to one-third of the DBP.
Pulse wave velocity and arterial stiffness
Carotid-femoral pulse wave velocity (PWV) was ana-
lyzed with an automatic device (CompliorW; Colson) by
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an experienced observer blinded to clinical characteristics.
Briefly, common carotid artery and femoral artery pres-
sure waveforms were recorded non-invasively using a
pressure-sensitive transducer (TY-306-FukudaW; Fukuda;
Tokyo, Japan). The distance between the recording sites
(D) was measured, and PWV was automatically calculated
as PWV=D/t, where (t) means pulse transit time. Mea-
surements were repeated over 10 different cardiac cycles,
and the mean was used for the final analysis. The valid-
ation and its reproducibility have been previously
described, and increased arterial stiffness was defined as
PWV≥ 12 m/s [16,25].
Coronary artery disease scores
Twenty coronary segments were scored: each vessel was
divided into three segments (proximal, medial, and
distal), except for the secondary branches of the right
coronary artery (posterior ventricular and posterior
descending), which were divided into proximal and distal
segments. Stenosis higher than 50% in any coronary seg-
ment was graded 1 point and the sum of points for all
20 segments constituted the Extension Score. Lesion se-
verity was calculated as follows: none and irregularities,
0 points; <50%, 0.3 points; 50–70%, 0.6 points; >70–
90%, 0.8 points; and >90–100%, 0.95 points. The
Severity Score was calculated through the sum of points
for all 20 coronary segments [17].
Genotyping
Genomic DNA from subjects was extracted from periph-
eral blood following standard salting-out procedure.
Genotypes for the MYLIP rs9370867 (p.N342S, c.
G1025A) polymorphism was detected by polymerase
chain reaction (PCR) followed by high resolution
melting (HRM) analysis with the Rotor Gene 6000W
instrument (Qiagen, Courtaboeuf, France) [26,27]. The
QIAgilityW (Qiagen, Courtaboeuf, France), an automated
instrument, was used according to instructions to optimize
the sample preparation step. One specific disc is able to
genotype 96 samples for this polymorphism [28].
Amplification of the fragment was performed using
the primer sense 5’- TTGTGGACCTCGTTTCAAGA -
3’ and antisense 5’- GCTGCAGTTCATGCTGCT -3’ (80
pairs base) for the rs9370867. A 40-cycle PCR was car-
ried out with the following conditions: denaturation of
the template DNA for first cycle of 94°C for 120 s, de-
naturation of 94°C for 20 s, annealing of 53.4°C for 20 s,
and extension of 72°C for 22 s. PCR was performed
using a 10 μL reactive solution (10 mM Tris–HCl,
50 mM KCl, pH 9.0; 2.0 mM MgCl2; 200 μM of each
dNTP; 0.5 U Taq DNA Polymerase; 200 nM of each
primer; 10 ng of genomic DNA template) with addition
of fluorescent DNA-intercalating SYTO9W (1.5 μM;
Invitrogen, Carlsbad, USA).
In the HRM phase, the Rotor Gene 6000W measured
the fluorescence in each 0.1°C temperature increase in
the range of 73-85°C. Melting curves were generated by
the decrease in fluorescence with the increase in the
temperature; and in analysis, nucleotide changes result
in three different curve patterns (Figure 1). Samples of
the three observed curves were analyzed using bidirectional
sequencing as a validation procedure (ABI Terminator
Sequencing KitW and ABI 3500XL SequencerW - Applied
Biosystems, Foster City, CA, USA). The two methods gave
identical results in all tests. The wild-type, heterozygous
and mutant homozygous genotypes for the rs9370867
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Figure 1 Graphs of the MYLIP rs9370867 (p.N342S, c.G1025A) nucleotide changes results in different curve patterns using high
resolution melting analysis. A: Graph of normalized fluorescence by temperature. B: Graph of normalized fluorescence (based on genotype 2)
by temperature. C: Graph of melting curve analysis (fluorescence differential/temperature differential). 1: wild-type genotype (GG); 2: heterozygous
genotype (GA); 3: mutant homozygous genotype (AA).
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could be easily discernible by HRM analysis. In addition,
4% of the samples were randomly selected and reanalyzed
as quality controls and gave identical results.
Statistical analysis
Categorical variables are presented as percentage while
continuous variables are presented as mean ± standard
deviation. Chi-square test was performed for compara-
tive analysis of gender, ethnicity, hypertension, diabetes,
hyperlipidemia, increased arterial stiffness, and smoking
frequencies according to MYLIP polymorphism. Chi-
square test was also performed for the Hardy-Weinberg
equilibrium. ANOVA test was performed for comparing
the age, BMI, biochemical data, blood pressures, PWV,
and angiographic data means according to MYLIP
polymorphism. Tukey's post hoc test was performed to
identify the different group. Biochemical data, blood
pressures, and angiographic data were adjusted for age,
gender, and ethnicity. PWV was adjusted for age, gender,
MBP, and ethnicity.
The analysis stratified by hyperlipidemia was performed
according to Weissglas-Volkov et al.‘s inclusion and exclu-
sion criteria [8,15]. Fasting serum TG> 200 mg/dL for the
cases, TG< 150 mg/dL for the controls, and subjects with
morbid obesity (BMI> 40 kg/m2) or type 2 diabetes melli-
tus were excluded. The subjects were classified as high-TC
if their serum TC levels were≥ 240 mg/dL and normal TC
if their serum TC levels were< 240 mg/dL in the absence
of lipid lowering medication. The subjects were also classi-
fied as combined hyperlipidemia if their serum TC and TG
levels were≥ 240 mg/dL and> 200 mg/dL, and as controls
if TC and TG levels were< 240 mg/dL and< 150 mg/dL,
respectively [8,15]. All statistical analyses were carried out
using the SPSS software (v. 16.0), with the level of signifi-
cance set at p< 0.05.
Results
General characteristics according to MYLIP polymorphism
Table 1 summarizes general characteristics of both studied
samples.
No difference in the frequencies of hyperlipidemia,
diabetes, increased arterial stiffness, and smoking status
according to MYLIP polymorphism was found. Only
hypertension frequency presented a trend (p = 0.05) in
the general population (Table 1).
In both general population and patient samples, the
MYLIP rs9370867 polymorphism was differently distributed
according to ethnicity (Table 1). In the general population,
the frequencies of the MYLIP rs9370867 A variant allele
and of the homozygous genotype (AA) was higher in
Whites (45.8% and 22.1%) compared with Blacks (15.2%
and 3.1%) (p< 0.001 and p< 0.001, respectively). In the
patients submitted to coronary angiography, the frequencies
of the MYLIP rs9370867 A variant allele and of the
homozygous genotype (AA) was higher in Whites (44.6%
and 20.7%) compared with Blacks (21.3% and 5.9%) (p
< 0.001 and p< 0.001, respectively). The genotypic distri-
bution for the MYLIP rs9370867 polymorphism was in
Hardy–Weinberg equilibrium according to ethnic groups.
Biochemical, hemodynamic, and angiographic data
according to MYLIP polymorphism
Table 2 summarizes biochemical, hemodynamic, and
angiographic data of both studied samples.
There was no association of the MYLIP rs9370867
genotypes with TC, LDL-C, HDL-C, triglycerides, and
glycemia values in both samples (Table 2).
In the general population, subjects carrying GG
genotypes had higher SBP, DBP, and MBP values
(129.0±23.3; 84.9± 14.6; 99.5± 16.8 mmHg) compared
with subjects carrying AA genotypes (123.7± 19.5;
81.6± 11.8; 95.6± 13.6 mmHg) (p=0.01; p=0.02; p= 0.01,
respectively), even after adjustment for age, gender, and
ethnicity (Table 2). This difference was not found in the
patient sample.
No association of the studied polymorphism with
PWV values (available for the general population
sample) or with angiographic data (extension and sever-
ity scores, available for the patient sample) was observed
(Table 2).
Analysis stratified by hyperlipidemia, gender, and
ethnicity
The analysis stratified by hyperlipidemia was performed
according to Weissglas-Volkov et al.‘s inclusion and exclu-
sion criteria (see Methods section for details) [8,15]. In
this analysis, the sub-groups (controls and dyslipidemic
subjects) presented similar result as the total sample in
both general population and patient samples, even after
adjustment for covariates. In the sub-groups, no associ-
ation of the variables according to genotypes was found
and no difference in the variant allele frequency between
sub-groups was observed (p> 0.05). In addition, the ana-
lysis stratified by gender and ethnicity did not identify
significant results in both studied samples.
Discussion
A recent study reported that MYLIP rs9370867 poly-
morphism was associated with TC levels in a Mexican
dyslipidemic sample and this genetic data was supported
by functional data, which demonstrated that rs9370867
influences plasma cholesterol levels by modifying the
degradation of the LDL-receptor [15]. In this context
and in an attempt to replicate this important association,
our main finding was that the polymorphism did not
influence the lipid profile in both Brazilian samples
studied: general population and patients submitted to
coronary angiography.
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Here, the frequency of the A was much higher in
Whites compared with Blacks. Previous studies reported
that in African and Asian groups, the frequency is rela-
tively low at 2% - 8%, whereas in European descent, the
frequency is much higher at 49% - 60% [15,29,30]. The
Brazilian population is one of the most heterogeneous in
the world, and it is a mixture of different ethnic groups,
composed mainly of European descent, African descent,
and Amerindians. Thus, adjustement for ethnicity plus
other covariates were performed and an analysis strati-
fied by ethnicity was made. Nevertheless, no significant
result was found. In this point there is a limitation: gen-
etic markers of ancestry have not been used; however, a
validated questionnaire for ethnicity classification was
used.
In the same way, this variation of the allele frequency
among ethnicity influenced blood pressures data in gen-
eral population samples. SBP, DBP, and MBP values were
higher in GG genotype group (major frequency of
Blacks) while lower values were observed in AA geno-
type group (minor frequency of Blacks). The adjustment
for covariates plus ethnicity was not able to exclude the
participation of the ethnicity variable in the observed
results. But, in analysis stratified by ethnicity, this find-
ing was not found in any ethnicity group. Corroborating
with this observation, our group demonstrated in a
Table 1 General characteristics according to MYLIP rs9370867 genotypes
General population Genotypes p value
(n= 1295, 100%) GG (n= 547) GA (n= 571) AA (n= 177)
Age (years) 44.1 ± 10.9 45.1 ± 10.7 45.8 ± 10.5 0.14
Gender, female (%) 52.7 54.1 55.9 0.72
Ethnicitya (%)
White 30.7 47.2 22.1
Intermediate 45.2 44.4 10.4 <0.001
Black 72.7 24.2 3.1
Other 47.9 45.3 6.8
Hypertensionb (%) 48.6 45.2 36.1 0.05
Diabetesc (%) 6.4 8.1 6.2 0.49
Hyperlipidemiad (%) 26.3 27.1 27.7 0.33
Increased arterial stiffnesse (%) 16.1 14.9 10.2 0.20
Smokersf (%) 24.9 24.5 24.3 0.58
Body mass indexg (Kg/m2) 26.4 ± 5.2 26.3 ± 4.7 25.9 ± 4.5 0.60
Patients submitted to coronary angiography Genotypes p value
(n= 1425, 100%) GG (n= 545) GA (n= 633) AA (n= 247)
Age (years) 59.5 ± 10.6 60.2 ± 10.1 60.1 ± 10.3 0.55
Gender, female (%) 41.7 41.2 36.0 0.29
Ethnicity (%)
White 31.6 47.7 20.7
Intermediate 44.8 42.3 12.9 <0.001
Black 63.2 30.9 5.9
Other 91.2 8.8 0
Hypertension (%) 74.6 73.4 67.1 0.08
Diabetes (%) 35.4 34.1 34.2 0.56
Hyperlipidemia (%) 57.6 61.1 56.2 0.69
Smoker (%) 32.7 37.0 38.1 0.21
Body mass index (Kg/m2) 27.8 ± 4.9 27.6 ± 4.7 27.7 ± 4.9 0.67
aEthnicity was categorized in White, Black, Intermediate (person with admixture between White and Black) and other (Amerindians and Oriental descent).
bHypertension was defined as mean systolic blood pressure ≥ 140 mmHg and/or diastolic blood pressure ≥ 90 mmHg and/or use of anti-hypertension drugs.
cDiabetes was defined as fasting glucose ≥ 126 mg/dL and/or use of hypoglycemic drugs.
dHyperlipidemia was defined as total-cholesterol ≥ 240 mg/dL, low density lipoprotein-cholesterol ≥ 160 mg/dL, and/or use of hypolipidemic drugs.
eIncreased arterial stiffness was defined as pulse wave velocity ≥ 12 m/s.
fIndividuals who had ever smoked more than five cigarettes per day for the last a year were classified as smokers.
gAdjusted for age and gender.
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recent study that SBP, DBP, and MBP values were higher
in Black individuals than in the other ethnic groups in
the Brazilian general population (p< 0.001) [16]. Thus
there is no evidence that the MYLIP studied polymorph-
ism influences blood pressures.
In this study, the replication of the previously identi-
fied association was not found in both general popula-
tion and patient samples. Two GWAS of populations of
European descent have identified MYLIP genetic loci
contributing to variation in serum lipids [12,13].
Weissglas-Volkov et al. investigated the MYLIP region in
Mexican individuals in order to restrict the associated
region and identified the variant p.N342S (rs9370867).
They associated this substitution with cholesterol levels
in a Mexican dyslipidemic study sample [15].
It is important to report that the mentioned study
have only observed the association in Mexican dyslipi-
demic individuals. Our Brazilian general population
sample allowed a first assessment of this association in
a general population and, our second sample, patients
submitted to coronary angiography, allowed an analysis
with major frequency of dyslipidemic individuals. In
both samples, even after performing analysis according
to Weissglas-Volkov et al.‘s criteria (see Methods sec-
tion), no association was observed. The patterns of
linkage disequilibrium vary across populations and eth-
nicities according to previous studies [15,29,30]; thus, it
is plausible that one or more MYLIP functional poly-
morphisms could be differently distributed leading to
distinct findings.
Conclusion
Our findings indicate that association studies involving
this MYLIP variant can present distinct results according
to the studied population. In this moment, further stud-
ies are needed to reaffirm if the MYLIP p.N342S poly-
morphism is functional or not, and to identify other
functional markers in this locus.
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Table 2 Biochemical, hemodynamic, and angiographic data according to MYLIP rs9370867 genotypes
General population Genotypes p value
(n= 1295, 100%) GG (n= 547) GA (n= 571) AA (n= 177)
Total cholesterol (mg/dL) 213 ± 42.9 215.7 ± 45.8 213.5 ± 41.1 0.56
LDL-C (mg/dL) 142.3 ± 37.4 143.6 ± 40.8 140.9 ± 36.5 0.67
HDL-C (mg/dL) 46.0 ± 13.0 45.5 ± 12.1 45.9 ± 12.7 0.77
Triglycerides (mg/dL) 126.9 ± 87.1 141.3 ± 138.9 135.6 ± 95.2 0.10
Glycemia (mg/dL) 105.0 ± 30.2 104.3 ± 30.0 101.2 ± 27.1 0.33
Systolic blood pressure (mmHg) 129.0 ± 23.3a 127.2 ± 21.3a,b 123.7 ± 19.5b 0.01
Diastolic blood pressure (mmHg) 84.9 ± 14.6a 83.9 ± 13.9a,b 81.6 ± 11.8b 0.02
Mean blood pressure (mmHg) 99.5 ± 16.8a 98.3 ± 15.5a,b 95.6 ± 13.6b 0.01
Pulse wave velocity (m/s) 9.9 ± 2.3 9.9 ± 2.2 9.7 ± 1.9 0.15
Patients submitted to coronary angiography Genotypes p value
(n= 1425, 100%) GG (n= 545) GA (n= 633) AA (n= 247)
Total cholesterol (mg/dL) 228.4 ± 48.7 232.5 ± 51.4 228.6 ± 50.2 0.39
LDL-C (mg/dL) 148.1 ± 45.0 149.6 ± 41.3 147.5 ± 48.8 0.86
HDL-C (mg/dL) 43.0 ± 12.4 42.4 ± 11.5 42.0 ± 11.4 0.64
Triglycerides (mg/dL) 184.0 ± 124.6 182.3 ± 147.6 188.1 ± 147.7 0.87
Glycemia (mg/dL) 128.0 ± 50.8 128.9 ± 61.0 130.9 ± 59.7 0.82
Systolic blood pressure (mmHg) 152.7 ± 31.6 150.4 ± 35.8 143 ± 38.1 0.21
Diastolic blood pressure (mmHg) 82.4 ± 17.0 82.4 ± 14.6 80.7 ± 13.1 0.78
Ejection fraction (%) 59.1 ± 15.6 61.2 ± 14.6 57.4 ± 14.9 0.17
Extension score 2.2 ± 1.7 2.2 ± 1.6 2.2 ± 1.5 0.89
Severity score 1.6 ± 1.3 1.6 ± 1.2 1.7 ± 1.3 0.97
Continuous data are expressed as mean ± standard deviation.
Values with different superscript letters are significantly different (Tukey’s post hoc test).
HDL-C: high density lipoprotein; LDL-C: low density lipoprotein.
Biochemical data, blood pressures, ejection fraction, and angiographic scores were adjusted for age, gender, and ethnicity.
Pulse wave velocity data was adjusted for age, gender, mean blood pressure, and ethnicity.
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